Jalid Sehouli

44.0k total citations · 3 hit papers
866 papers, 19.2k citations indexed

About

Jalid Sehouli is a scholar working on Reproductive Medicine, Oncology and Surgery. According to data from OpenAlex, Jalid Sehouli has authored 866 papers receiving a total of 19.2k indexed citations (citations by other indexed papers that have themselves been cited), including 491 papers in Reproductive Medicine, 260 papers in Oncology and 225 papers in Surgery. Recurrent topics in Jalid Sehouli's work include Ovarian cancer diagnosis and treatment (450 papers), Endometrial and Cervical Cancer Treatments (174 papers) and Intraperitoneal and Appendiceal Malignancies (140 papers). Jalid Sehouli is often cited by papers focused on Ovarian cancer diagnosis and treatment (450 papers), Endometrial and Cervical Cancer Treatments (174 papers) and Intraperitoneal and Appendiceal Malignancies (140 papers). Jalid Sehouli collaborates with scholars based in Germany, United States and Belgium. Jalid Sehouli's co-authors include Elena Ioana Braicu, Christina Fotopoulou, W. Lichtenegger, Alexander Mustea, Carsten Denkert, Ignace Vergote, Andreas du Bois, Philipp Harter, Rolf Richter and Silvia Darb‐Esfahani and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Nature Communications.

In The Last Decade

Jalid Sehouli

815 papers receiving 18.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ovarian cancer

2016 842 citations Jalid Sehouli et al. profile →
Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse

2010 410 citations Éric Pujade-Lauraine, Uwe Wagner et al. Journal of Clinical Oncology profile →
The Notch and Wnt pathways regulate stemness and differentiation in human fallopian tube organoids

2015 344 citations Jalid Sehouli, Christina Fotopoulou et al. profile →

Peers

Countries citing papers authored by Jalid Sehouli

Since Specialization

Citations

This map shows the geographic impact of Jalid Sehouli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jalid Sehouli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jalid Sehouli more than expected).

Fields of papers citing papers by Jalid Sehouli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jalid Sehouli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jalid Sehouli. The network helps show where Jalid Sehouli may publish in the future.

Co-authorship network of co-authors of Jalid Sehouli

This figure shows the co-authorship network connecting the top 25 collaborators of Jalid Sehouli. A scholar is included among the top collaborators of Jalid Sehouli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jalid Sehouli. Jalid Sehouli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Endometriosis and Opioid Receptors: Are Opioids a Possible/Promising Treatment for Endometriosis? 2023 ·International Journal of Molecular Sciences ·(unknown), Renata Voltolini Velho, Jalid Sehouli, Sylvia Mechsner	4
2	2022-RA-276-ESGO Value of surgical cytoreduction for subsequent ovarian cancer relapse in patients previously treated with chemotherapy alone at 1st-relapse: a subanalysis of the DESKTOP III/ENGOT-ov20 trial 2022 ·International Journal of Gynecological Cancer ·Christina Fotopoulou, Jalid Sehouli, Ignace Vergote, Alexander Reuß, Marianne Leheurteur, Felix Hilpert, Aude-Marie Savoye, Stefano Greggi, (unknown), B. Resch, Michel Gatineau, Jean Lévêque, Rongyu Zang, Pernille Tine Jensen, (unknown), (unknown), Francesco Raspagliesi, Ulla Peen, Andreas du Bois, Philipp Harter	1
3	2022-RA-1546-ESGO Potential approach to overcome checkpoint inhibitor resistance in a long-term survivor patient with recurrent endometrial carcinoma 2022 ·International Journal of Gynecological Cancer ·(unknown), Sara Alavi, (unknown), (unknown), Elena Ioana Braicu, Klaus Pietzner, (unknown), Wolfgang Schmitt, Jalid Sehouli	0
4	2022-RA-1673-ESGO The digital trans-african E-health network- a clinical partnership experience 2022 ·International Journal of Gynecological Cancer ·Sara Nasser, Jalid Sehouli, (unknown), (unknown), (unknown), Andreas Ullrich, Andreas M. Kaufmann	2
5	2022-RA-672-ESGO Comparison of quality of life in patients with platinum-sensitive recurrent ovarian, fallopian tube and peritoneal cancer treated with trabectedin plus pegylated liposomal doxorubicin (PLD) or standard platinum-based therapy: Data look of the NOGGO S16/COMPASS trial 2022 ·International Journal of Gynecological Cancer ·Radoslav Chekerov, Mustafa Deryal, Bahriye Aktas, Robert Röhle, (unknown), Marco Johannes Battista, Christian M. Kurbacher, Pauline Wimberger, (unknown), Jana Barinoff, (unknown), (unknown), Maximilian Klar, (unknown), (unknown), Gülten Oskay-Özcelik, Thomas Illmer, Thorsten Oliver Götze, Klaus Pietzner, Jalid Sehouli	1
6	2022-RA-1154-ESGO Ovarian cancer management. Who cares for the Patient? A single case observational study 2022 ·International Journal of Gynecological Cancer ·(unknown), Klaus Pietzner, Mustafa Zelal Muallem, (unknown), Jalid Sehouli	0
7	2022-RA-991-ESGO Assessment of high-risk human papillomavirus infections and cervical dysplasia in human immunodeficiency virus-positive pregnant women in germany: a prospective cross-sectional two-center study 2022 ·International Journal of Gynecological Cancer ·(unknown), (unknown), Jalid Sehouli, Jan-Peter Siedentopf, (unknown), Irene Alba‐Alejandre, Katharina Weizsäcker, Wolfgang Henrich, (unknown), (unknown)	1
8	2022-RA-1287-ESGO Case report of a patient with relapsed ovarian cancer and therapy with all three approved PARP-inhibitors 2022 ·International Journal of Gynecological Cancer ·(unknown), Elena Ioana Braicu, Jacek Grabowski, Klaus Pietzner, Jalid Sehouli	0
9	2022-RA-1057-ESGO Outcomes of gynaecological cancer surgery during the covid-19 pandemic: results from the international, multicenter, prospective covidsurg-gynaecological cancer study 2022 ·International Journal of Gynecological Cancer ·Christina Fotopoulou, (unknown), (unknown), James Glasbey, (unknown), Luis Chiva, Anna Fagotti, (unknown), Rahel Ghebre, Murat Gutelkin, Thomas O. Konney, Joseph Ng, René Pareja, Rajkumar Kottayasamy Seenivasagam, Jalid Sehouli, (unknown), Aneel Bhangu, Elaine Leung, Sudha Sundar	2
10	2022-RA-1548-ESGO Trial in progress update on ENGOT-cx8/GOG-3024/innovaTV 205: addition of a new cohort using first-line tisotumab vedotin + pembrolizumab + carboplatin ± bevacizumab in recurrent/metastatic cervical cancer 2022 ·International Journal of Gynecological Cancer ·Ignace Vergote, Mansoor Raza Mirza, Jalid Sehouli, (unknown), Fatih Köse, David Cibula, Anneke M. Westermann, Dearbhaile Catherine Collins, Susana Banerjee, Ana Oaknin, Ibrahima Soumaoro, (unknown), Bradley J. Monk	1
11	2022-RA-1644-ESGO The need for a unified appraoch in patient advocacy for global women´s health: a PARSGO initiative 2022 ·International Journal of Gynecological Cancer ·Sara Nasser, (unknown), (unknown), (unknown), (unknown), Jalid Sehouli	1
12	EZH2 Loss Drives Resistance to Carboplatin and Paclitaxel in Serous Ovarian Cancers Expressing ATM 2019 ·Molecular Cancer Research ·(unknown), (unknown), Ruan van Rensburg, Ellen Honisch, Martina Rudelius, (unknown), (unknown), (unknown), Elena Ioana Braicu, Jalid Sehouli, Silvia Darb‐Esfahani, Annette Staebler, Andreas D. Hartkopf, Sara Y. Brucker, D. Wallwiener, Ines Beyer, Dieter Niederacher, Tanja Fehm, Markus F. Templin, Hans Neubauer	8
13	Accumulated Metabolites of Hydroxybutyric Acid Serve as Diagnostic and Prognostic Biomarkers of Ovarian High-Grade Serous Carcinomas 2016 ·Cancer Research ·Mika Hilvo, Inês de Santiago, Peddinti Gopalacharyulu, Wolfgang Schmitt, Jan Budczies, Marc Kuhberg, Manfred Dietel, Tero Aittokallio, Florian Markowetz, Carsten Denkert, Jalid Sehouli, Christian Frezza, Silvia Darb‐Esfahani, Elena Ioana Braicu	70
14	Polo-like Kinase Plk2 Is an Epigenetic Determinant of Chemosensitivity and Clinical Outcomes in Ovarian Cancer 2011 ·Cancer Research ·Nelofer Syed, Helen M. Coley, Jalid Sehouli, Dominique Koensgen, Alexander Mustea, Peter W. Szlosarek, Iain A. McNeish, Sarah P. Blagden, Peter Schmid, David P. Lovell, Eleftheria Hatzimichael, Tim Crook	49
15	Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse breakdown → 2010 ·Journal of Clinical Oncology ·Éric Pujade-Lauraine, Uwe Wagner, (unknown), Val Gebski, M. Heywood, P. Vasey, Birgit Volgger, Ignace Vergote, Sandro Pignata, Annamaria Ferrero, Jalid Sehouli, Alain Lortholary, Gunnar B. Kristensen, Christian Jackisch, Florence Joly, Chris Brown, Nathalie Le Fur, Andreas du Bois	410
16	Atypical Protein Kinase C ζ Exhibits a Proapoptotic Function in Ovarian Cancer 2010 ·Molecular Cancer Research ·Irina Nazarenko, Marcel Jenny, Jana Keil, (unknown), (unknown), Jalid Sehouli, Stefan Legewie, (unknown), Wilko Weichert, Silvia Darb‐Esfahani, Manfred Dietel, Reinhold Schäfer, Florian Ueberall, Christine Sers	26
17	An Illegitimate microRNA Target Site within the 3′ UTR of MDM4 Affects Ovarian Cancer Progression and Chemosensitivity 2010 ·Cancer Research ·(unknown), Anja Böhnke, Eleonora Leucci, Søren Jensby Nielsen, Irina Lambertz, Stefanie Hammer, (unknown), (unknown), Anja Wolf, Elise Gradhand, Katharina Balschun, Elena Ioana Braicu, Jalid Sehouli, Silvia Darb‐Esfahani, Carsten Denkert, Christoph Thomssen, Steffen Hauptmann, Anders H. Lund, Jean‐Christophe Marine, Frank Bartel	141
18	Incidence of Venous Thromboembolism in Patients With Ovarian Cancer Undergoing Platinum/Paclitaxel–Containing First-Line Chemotherapy: An Exploratory Analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group 2008 ·Journal of Clinical Oncology ·Christina Fotopoulou, Andreas duBois, Alexandros N. Karavas, Ralf Ulrich Trappe, Behnaz Aminossadati, Barbara Schmalfeldt, Jacobus Pfisterer, Jalid Sehouli	74
19	An Integrated Clinical-Genomics Approach Identifies a Candidate Multi-Analyte Blood Test for Serous Ovarian Carcinoma 2007 ·Clinical Cancer Research ·Ivo Meinhold‐Heerlein, Dirk Bauerschlag, Yingyao Zhou, Lisa M. Sapinoso, Keith A. Ching, Henry F. Frierson, Karen Bräutigam, Jalid Sehouli, Elmar Stickeler, Dominique Könsgen, Felix Hilpert, Constantin S. von Kaisenberg, Jacobus Pfisterer, Thomas Bauknecht, W. Jonat, Norbert Arnold, Garret M. Hampton	41
20	Mass Spectrometry–Based Metabolic Profiling Reveals Different Metabolite Patterns in Invasive Ovarian Carcinomas and Ovarian Borderline Tumors 2006 ·Cancer Research ·Carsten Denkert, Jan Budczies, Tobias Kind, Wilko Weichert, (unknown), Jalid Sehouli, Silvia Niesporek, Dominique Könsgen, Manfred Dietel, Oliver Fiehn	304

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact